Work

Supplementary Material from Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Material

DOI: 10.1158/1078-0432.22474214.v1

Authors: David S. Hong, Patricia LoRusso, Omid Hamid, Filip Janku, Muaiad Kittaneh, Daniel V.T. Catenacci, Emily Chan, Tanios Bekaii-Saab, Shirish M. Gadgeel, Robert D. Loberg, Benny M. Amore, Yuying C. Hwang, Rui Tang, Gataree Ngarmchamnanrith, Eunice L. Kwak

Institutions: The University of Texas MD Anderson Cancer Center, Yale Cancer Center, Yale University, Angeles Clinic and Research Institute, Loyola University Chicago, University of Chicago, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Mayo Clinic, Mayo Clinic in Arizona, Mayo Clinic Hospital, University of Michigan, The Barbara Ann Karmanos Cancer Institute, Michigan Medicine, Amgen (United States), Massachusetts General Hospital

Language: English

Topic: Cancer Mechanisms and Therapy

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361962539

Cites: 2

Cited by:

Related to: 10